FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 319 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab April 16, 2024 Scottish Soccer Star Who Just Announced Breast Cancer Diagnosis Scores Goal,... December 21, 2020 FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer July 8, 2020 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During... October 19, 2020 Load more HOT NEWS EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in... Woman’s Doctors Kept Telling Her She Was ‘Just Overweight,’ Ended Up... Patients with Early Stage NSCLC Have a Higher TMB in Comparison... FDA Approves Capivasertib with Fulvestrant for Breast Cancer
